Biopharma M&A
Recent deal announcements covering the last 60 days. Deal activity continues to be strong, led by Pfizer’s winning $14 billion bid for Medivation over the likes of Sanofi and Gilead. Biopharma M&A
Nivolumad Therapy in Kidney Cancer
The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting. This is terrific for patients of this difficult disease, as well as for Bristol-Meyers Squibb who markets Optivo. Nivolumad therapy in kidney cancer
FDA Final Guidance – General Wellness Devices
Here is a brief summary of the FDA guidance document (which is only 13 pages) for general wellness devices that was released July 29. Good news for many fitness tracking, weight loss, and sleep management products that will be exempt from oversight if they meet the “low risk” criteria. FDA final guidance - General Wellness [...]